Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zymeworks (ZYME) EBT (2021 - 2025)

Zymeworks' EBT history spans 5 years, with the latest figure at -$41.5 million for Q4 2025.

  • On a quarterly basis, EBT fell 133.15% to -$41.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$79.8 million, a 31.61% increase, with the full-year FY2025 number at -$79.8 million, up 31.61% from a year prior.
  • EBT hit -$41.5 million in Q4 2025 for Zymeworks, down from -$18.3 million in the prior quarter.
  • Over the last five years, EBT for ZYME hit a ceiling of $320.4 million in Q4 2022 and a floor of -$72.7 million in Q1 2022.
  • Historically, EBT has averaged -$15.6 million across 5 years, with a median of -$30.6 million in 2024.
  • Biggest five-year swings in EBT: soared 890.75% in 2022 and later plummeted 133.15% in 2025.
  • Tracing ZYME's EBT over 5 years: stood at -$40.5 million in 2021, then soared by 890.75% to $320.4 million in 2022, then tumbled by 105.99% to -$19.2 million in 2023, then grew by 7.36% to -$17.8 million in 2024, then plummeted by 133.15% to -$41.5 million in 2025.
  • Business Quant data shows EBT for ZYME at -$41.5 million in Q4 2025, -$18.3 million in Q3 2025, and $2.1 million in Q2 2025.